There is an unmet need for targeted therapies for mitochondrial disease and here, for the first time, we demonstrate that two SSOs targeting the TIMMDC1 c.597-1340A>G variant can restore mitochondrial function in patient cells, suggesting that the functional effect of the aberrant splicing can be repaired. Here, TIMMDC1 is linked to inborn mitochondrial metabolism disorder.